NLS Biotech News

The first subject has been dosed in the company’s ODIN Phase 1/2 clinical trial evaluating TH9619, a first-in-class MTHFD1/2 inhibitor. 

Evaxion is advancing its novel multi-component cytomegalovirus (CMV) vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program.

Lytix Biopharma has announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma.

The company has initiated a Phase IIa clinical trial to evaluate the safety and biomarker-based efficacy of AT-001 in individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).

The company has presented immune response data on ruxotemitide (formerly LTX-315/VP-315) at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland.

The multicentre, phase 3 human clinical trial will evaluate the efficacy and safety of the company’s pharmaceutical, Combined Metabolic Activator, in patients with Alzheimer’s disease.

The company has announced results from the 1,600-patient CAPTURE-HF study (Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-Invasive Multi-sensor Device).

The results show that the vaccine generates strong and long-lasting immune responses both at the mucosal surfaces and systemically.

The company has announced positive results from the ARIA-2 clinical study.

Herantis Pharma has announced positive topline results from its Phase 1b trial of HER-096 in people living with Parkinson’s disease, with all primary and secondary endpoints met.